UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
_______________
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 7, 2017
ULTRAGENYX PHARMACEUTICAL INC.
(Exact name of registrant as specified in charter)
Delaware | 001-36276 | 27-2546083 |
(State or other jurisdiction | (Commission | (IRS Employer |
60 Leveroni Court, Novato, California | 94949 |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (415) 483-8800
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory Note
On November 7, 2017, Ultragenyx Pharmaceutical Inc. (the “Company” or “Ultragenyx”) filed a current report on Form 8-K (the “Original Filing”) in connection with the closing on November 7, 2017 of the merger of Mystic River Merger Sub Inc., a wholly-owned subsidiary of the Company, with and into Dimension Therapeutics, Inc. In connection with the transactions disclosed in Item 2.01 of the Original Filing (the “Transactions”), the Company is filing this Form 8-K/A to provide the unaudited pro forma condensed combined financial statements of the Company after giving effect to the Transactions, as required by Item 9.01(b) of Form 8-K. This information was not included in the Original Filing.
Item 9.01Financial Statements and Exhibits
(b)Pro Forma Financial Information.
| (1) | The unaudited pro forma condensed combined balance sheet of the Company as of September 30, 2017, and the unaudited pro forma condensed combined statement of operations for the year ended December 31, 2016 and for the nine months ended September 30, 2017, and the related notes thereto, are attached hereto as Exhibit 99.2. |
(d) Exhibits
Exhibit No.Description
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Ultragenyx Pharmaceutical Inc.
By: /s/ Shalini Sharp
Name: Shalini Sharp
Title: Executive Vice President, Chief Financial
Officer